Simon Hw Buckingham
United States of America
Simon has been a member of the Board of Directors since July 2012. He has over 25 years’ experience in the global pharmaceutical industry across a range of functions and a variety of therapeutic areas. Now based in Sydney, Simon is currently a senior global advisor to Actelion, one of the world’s leading biopharmaceutical companies, and is a director of Actelion Australia. He was President, Global Corporate and Business Development at Actelion from 2005-2011, a position which spanned licensing, M&A, alliance management and corporate strategic planning. Simon served as President, North America and Asia-Pacific at Actelion from 2000-2005, with responsibility for all commercial operations in the region. He was the founding President of Actelion Pharmaceuticals US. From 1998-2000 he worked in sales and marketing for Parke-Davis (now part of Pfizer) in the US and prior to that served in roles in sales, marketing and development at Roche, both in Switzerland and Australia, for 9 years. Simon is currently a non-executive director of: Vaxxilon AG, a European based start-up, founded by the Max Planck Society and Actelion, dedicated to the discovery, development and commercialisation of innovative synthetic carbohydrate vaccines; Admedus Limited; and the Can Too Foundation, a non-profit organisation raising funds for cancer research. He holds a Bachelor of Veterinary Science degree from the University of Sydney, a PhD from the University of Melbourne, a Graduate Management Qualification from the AGSM, University of NSW and is a Graduate of the Australian Institute of Company Directors. Simon is a member of the Pharmaxis Audit Committee and has been chairman of the Remuneration & Nomination Committee since December 2016.
Pharmaxis is a pharmaceutical research company focussed on inflammation and fibrosis with a portfolio of products at various stages of development and approval.